Drug Trial Radar · NCT03157128
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
857
Actual
Start
May 2, 2017
Primary completion
Feb 14, 2025
Study completion Feb 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Loxo Oncology, Inc.
- First posted
- May 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Conditions
- Non-Small Cell Lung Cancer
- Medullary Thyroid Cancer
- Colon Cancer
- Any Solid Tumor
Interventions
LOXO-292Drug
Oral LOXO-292
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (cycle length = 28 days)
- Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Cycle 1 (cycle length = 28 days)
- Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) AssessmentTime frame: Approximately for up to 7 years 8 months
Locations
85 sites in 16 countries. Site status is shown where the registry gives one.
Mayo Clinic of Scottsdale
Scottsdale, Arizona
City of Hope National Medical Center
Duarte, California
UCLA Medical Center
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Kaiser Permanente
Oakland, California
Irvine Medical Center
Orange, California
University of California - San Diego
San Diego, California
UCSF Medical Center at Mission Bay
San Francisco, California
Kaiser Permanente Medical Center
Walnut Creek, California
Sarah Cannon Research Institute at HealthOne
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
Mayo Clinic in Florida
Jacksonville, Florida
Memorial Hospital Pembroke
Pembroke, Florida
Emory University
Atlanta, Georgia
University of Chicago Medicine-Comprehensive Cancer Center
Chicago, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
University of Maryland Medical Center
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
START Midwest
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University Medical School
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Roswell Park Cancer Institute
Buffalo, New York
NYU Langone
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University Hospital
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania Hospital
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Sarah Cannon Research Institute SCRI
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
USO-Virginia Cancer Specialists, PC
Fairfax, Virginia
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.